IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents

References

• Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi: 10.1038/s41573-019-0028-1
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98–104. doi: 10.1002/ijc.20908
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098–2103. doi: 10.1182/blood.V95.6.2098
   PubMed Web of Science ®Google Scholar
• Seckinger A, Majocchi S, Moine V, et al. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol. 2023;16(1):117. doi: 10.1186/s13045-023-01516-3
   PubMed Web of Science ®Google Scholar
• Madsen AV, Kristensen P, Buell AK, et al. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats. MAbs. 2023;15(1):2189432. doi: 10.1080/19420862.2023.2189432
   PubMed Web of Science ®Google Scholar
• Cao M, Wang C, Chung WK, et al. Characterization and analysis of scFv-IgG bispecific antibody size variants. MAbs. 2018;10(8):1236–1247. doi: 10.1080/19420862.2018.1505398
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Kornberg R, editor. Annu Rev Biochem. 2013;82:775–797. doi: 10.1146/annurev-biochem-063011-092449
   PubMed Web of Science ®Google Scholar
• Madsen AV, Mejias-Gomez O, Pedersen LE, et al. Immobilization-free binding and affinity characterization of higher order bispecific antibody complexes using size-based microfluidics. Anal Chem. 2022;94(40):13652–13658. doi: 10.1021/acs.analchem.2c02705
   PubMed Web of Science ®Google Scholar
• Atwell S, Ridgway JBB, Wells JA, et al. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26–35. doi: 10.1006/jmbi.1997.1116
   PubMed Web of Science ®Google Scholar
• Lee HY, Contreras E, Register AC, et al. Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies. Sci Rep. 2019;9(1):3900. doi: 10.1038/s41598-019-40689-1
   PubMedGoogle Scholar
• Yanakieva D, Pekar L, Evers A, et al. Beyond bispecificity: controlled fab arm exchange for the generation of antibodies with multiple specificities. MAbs. 2022;14(1):2018960. doi: 10.1080/19420862.2021.2018960
   PubMed Web of Science ®Google Scholar
• Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45. doi: 10.1186/s13045-020-00876-4
   PubMed Web of Science ®Google Scholar
• Madsen AV, Mejias-Gomez O, Pedersen LE, et al. Structural trends in antibody-antigen binding interfaces: a computational analysis of 1833 experimentally determined 3D structures. Computat Struct Biotechnol J. 2024;23:199–211. doi: 10.1016/j.csbj.2023.11.056
   PubMed Web of Science ®Google Scholar
• Mandrup OA, Friis NA, Lykkemark S, et al. A novel heavy domain antibody library with functionally optimized complementarity determining regions. PLoS One. 2013;8(10):e76834. doi: 10.1371/journal.pone.0076834
   PubMed Web of Science ®Google Scholar
• Mejias-Gomez O, Madsen AV, Skovgaard K, et al. A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies. MAbs. 2023;15(1):2268255. doi: 10.1080/19420862.2023.2268255
   PubMed Web of Science ®Google Scholar
• Greiff V, Miho E, Menzel U, et al. Bioinformatic and statistical analysis of adaptive immune repertoires. Trends Immunol. 2015;36(11):738–749. doi: 10.1016/j.it.2015.09.006
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, et al. Five computational developability guidelines for therapeutic antibody profiling. Proceedings of the National Academy of Sciences of the United States of America. 2019;116:p. 4025–4030.
   Google Scholar
• Dengl S, Mayer K, Bormann F, et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11(1):4974. doi: 10.1038/s41467-020-18477-7
   PubMed Web of Science ®Google Scholar